|
|
|
|
|||||
|
|
|
New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.
Moderna Inc (NASDAQ:MRNA) shares are down on Monday, pulling back after recent updates highlighting its latest cancer trial results. Here’s what investors need to know.
The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined with Merck & Co Inc’s (NYSE:MRK) Keytruda.
In addition to the trial data, Moderna has multiple ongoing studies in collaboration with Merck, which could pave the way for a significant oncology franchise if successful.
Moderna burst onto the scene with Spikevax, its COVID-19 vaccine and first commercial product, but investors have since worried about how it will offset declining pandemic-era revenue. The encouraging long-term melanoma results go beyond a single drug, they reinforce confidence in Moderna's mRNA platform and its cancer partnership with Merck.
If larger trials replicate these outcomes and secure regulatory approvals, Moderna could build a multibillion-dollar oncology vaccine franchise, underpinning a higher and more sustainable valuation for MRNA shares.
Currently, the stock is trading 26.8% above its 20-day simple moving average (SMA) and 65.9% above its 100-day SMA, demonstrating strong longer-term performance. Over the past 12 months, shares have increased by 13.88% and are positioned closer to their 52-week highs than lows, indicating a generally positive trend.
The RSI is at 73.00, which is considered overbought territory, while the MACD is above its signal line, indicating bullish momentum. The combination of overbought RSI and bullish MACD suggests that while momentum is strong, traders should remain cautious of potential pullbacks.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm’s mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020.
As of August 2025, Moderna had 35 mRNA development candidates in clinical studies across various therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. The recent trial results not only validate its mRNA platform but also highlight its potential to establish a significant presence in the oncology market.
Investors are looking ahead to the next earnings report on Feb. 13.
Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $36.59. Recent analyst moves include:
Below is the Benzinga Edge scorecard for Moderna, highlighting its strengths and weaknesses compared to the broader market:
–Momentum: Strong (Score: 82.94) — Stock is outperforming the broader market.
The Verdict: Moderna’s Benzinga Edge signal reveals a strong momentum setup. While the stock shows positive trends, investors should be mindful of the overbought conditions indicated by the RSI.
Significance: Because MRNA carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.
MRNA Price Action: Moderna shares were down 2.32% at $47.60 at the time of publication on Monday, according to Benzinga Pro data.
Image: Shutterstock
| 38 min | |
| 1 hour | |
| 1 hour | |
| 2 hours | |
| 4 hours | |
| 5 hours | |
| 6 hours | |
| 6 hours | |
| 7 hours | |
| 9 hours | |
| Jan-25 | |
| Jan-25 | |
| Jan-25 | |
| Jan-25 | |
| Jan-25 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite